Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy.
Serefhanoglu
Songul
S
Buyukasik
Yahya
Y
Goker
Hakan
H
Sayinalp
Nilgun
N
Haznedaroglu
Ibrahim Celalettin
IC
Aksu
Salih
S
Ozcebe
Osman Ilhami
OI
Turgut
Mehmet
M
Aslan
Rahmi
R
Ozdemir
Evren
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D014212:Tretinoin / Q000008:administration & dosage* / Q000009:adverse effects; D014421:Turkey
D018943:Anthracyclines; D014212:Tretinoin; D015255:Idarubicin